title: Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia.
abstract: BACKGROUND
  Magnesium sulphate remains the drug of choice for both prevention and treatment of women with eclampsia. Regimens for administration of this drug have evolved over the years, but have not yet been formally evaluated.
  
  
  OBJECTIVE
  To assess the comparative effects of alternative regimens for the administration of magnesium sulphate when used for the care of women with pre-eclampsia or eclampsia, or both.
  
  
  METHODS
  We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2010).
  
  
  METHODS
  Randomised trials comparing different regimens for administration of magnesium sulphate used for the care of women with pre-eclampsia or eclampsia, or both.
  
  
  METHODS
  All four review authors assessed trial quality and extracted data independently.
  
  
  RESULTS
  We identified 17 studies of which six (866 women) met the inclusion criteria: two trials (451 women) compared regimens for women with eclampsia and four (415 women) for women with pre-eclampsia.Treatment of eclampsia: one trial compared loading dose alone with loading dose plus maintenance therapy for 24 hours (401 women). There was no clear difference between the groups in the risk ratio (RR) of recurrence of convulsions (RR 1.13, 95% confidence interval (CI) 0.42 to 3.05) or stillbirth (RR 1.13, 95% CI 0.66 to 1.92), and the CIs are wide. One trial compared a low dose regimen with a standard dose regimen over 24 hours (50 women). This study was too small for any reliable conclusions about the comparative effects.Prevention of eclampsia: one trial compared intravenous with intramuscular maintenance regimen for 24 hours (17 women). This trial was too small for any reliable conclusions. Three trials compared short maintenance regimens postpartum with continuing for 24 hours after the birth (398 women), even taken together these trials were too small for any reliable conclusions.
  
  
  CONCLUSIONS
  Although strong evidence supports the use of magnesium sulphate for prevention and treatment of eclampsia, trials comparing alternative treatment regimens are too small for reliable conclusions.
authors.affiliation: Centre for Epidemiology and Biostatistics, University of Leeds, Bradford Institute for Health Research, Bradford Royal Infirmary, Duckworth Lane, Bradford, West Yorkshire, UK, BD9 6RJ.
authors.forename: Lelia
authors.initials: L
authors.lastname: Duley
authors.forename: Hosam E
authors.initials: HE
authors.lastname: Matar
authors.forename: Muhammad Qutayba
authors.initials: MQ
authors.lastname: Almerie
authors.forename: David R
authors.initials: DR
authors.lastname: Hall
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004461:Eclampsia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic
chemical_list: D000927:Anticonvulsants; D002121:Calcium Channel Blockers; D008278:Magnesium Sulfate